Products - Endometrial cancers | Topic | NICE

Showing 3 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
21 May 2025
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent TS ID 11808
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC